Patient experience and attitudes toward addressing the cost of breast cancer care.

Abstract

6551 Background: The American Society of Clinical Oncology has suggested that patient-physician discussion of costs is a component of high quality care. Little data exists on patients’ experience confronting costs or attitudes on how cost should be addressed. Methods: We distributed a self-administered anonymous paper survey to consecutive patients with breast cancer presenting for a routine visit within 5 years of diagnosis at an academic center. Survey questions addressed financial distress, experience and preferences concerning discussions of cost, and views on cost control. Results are primarily descriptive, with comparison among patients on the basis of disease stage using Fisher’s exact test. All p-values are 2-sided. Results: We surveyed 134 patients (response rate 86%). Median age was 61. 72% stage I-III disease, and 28% (n=36) had stage IV disease. 44% (n=57) reported at least a moderate level of financial distress. Only 14% (n=18) reported ever discussing costs with their doctor, though 94% (n=121) felt doctors should talk to patients about costs. 53% (n=69) felt doctors should discuss direct costs with patients but only 38% (n=49) felt doctors should consider costs to society or insurance companies in their decision-making. Patients with metastatic disease were significantly less likely than those with earlier stage disease to want doctors to consider societal costs (33% (n=24) vs 6% (n=2), p<0.01). 88% (n=114) reported concern over costs of cancer care, but there was no consensus on how to control costs. Only 3% (n=4) favored greater cost sharing and 9% (n=11) supported greater means testing. A minority (33%, n=43) supported reducing drug costs through government price controls (33% n=43). The majority endorsed generic substitution (59%, n=75) and preferential selection of drugs which prolong survival 53% (n=69). Conclusions: Although many patients with breast cancer want to discuss costs of care with their doctors, there is little consensus on the ideal content of these discussions. Few patients support consideration of societal costs in clinical decision-making. Further research is needed to evaluate the potential for patient-physician discussions of cost to contribute to affordable high quality cancer care.

Financial toxicity in cancer care

“…31 A survey of breast cancer patients found that 94% of respondents thought physicians should discuss costs of care, whereas 14% reported having actually had such discussions. 34 Another survey of cancer patients found that a majority (59%) wanted physicians to discuss out-of-pocket costs with them. However, a similar percentage (57%) reported that they did not integrate out-of-pocket costs into their individual medical decision-making process.…”

Financial distress among cancer survivors in Appalachian Kentucky

“…Cancer survivors' age and economic circumstances were also important in predicting financial distress. There is an obvious need for increased financial risk and cost of care conversations between cancer patients and their health care team; ideally, these conversations would promote shared decision‐making and improved cost‐related health literacy among patients . In addition, support services such as financial and insurance counseling, patient navigation, medication assistance programs, social services, and psychosocial oncology resources are needed to help patients manage medical and non‐medical financial issues related to their cancer care .…”

Financial discussions during cancer clinic consultations in Asia: Show me the money

“…The advent of new cancer therapies has improved prognosis but increased patients’ financial burden. American Society of Clinical Oncology thus recommends that oncologists discuss treatment costs during consultations, but many cancer patients report never having these discussions . An objective assessment of actual patient‐oncologist consultations is, however, rare, especially in Asia.…”